stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Net income
ACADIA Pharmaceuticals Inc.'s net income for fiscal 2025 was $391.0M, up 72.7% from $226.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $362.2M. Over the past ten years it has ranged from −$289.4M (fiscal 2017) to $391.0M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 3 consecutive fiscal years. ACADIA Pharmaceuticals Inc. ranks 15th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $391.0M | 72.66% |
| FY2024 | $226.5M | — |
| FY2023 | −$61.3M | — |
| FY2022 | −$216.0M | — |
| FY2021 | −$167.9M | — |
| FY2020 | −$281.6M | — |
| FY2019 | −$235.3M | — |
| FY2018 | −$245.2M | — |
| FY2017 | −$289.4M | — |
| FY2016 | −$271.4M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $53.5M | 69.92% |
| Jun 2026 | $31.5M | 766.10% |
| Mar 2026 | $3.6M | (98.67%) |
| Dec 2025 | $273.6M | 281.13% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | $362.2M |
| TNGX Tango Therapeutics, Inc. compare | −$123.7M |
| PBLS Parabilis Medicines, Inc. compare | −$170.9M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$220.5M |
| IRON Disc Medicine, Inc. compare | −$245.9M |
| RLAY Relay Therapeutics, Inc. compare | −$286.0M |
| XENE Xenon Pharmaceuticals Inc. compare | −$409.2M |
| DYN Dyne Therapeutics, Inc. compare | −$519.4M |
| VKTX Viking Therapeutics, Inc. compare | −$627.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ACAD
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement